Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1Heba Alshaker, Dmitri Pchejetski, Torsten Böhler et al.|Oncotarget|2016Cited by 36
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1Heba Alshaker, Dmitri Pchejetski, Qi Wang et al.|Scientific Reports|2017Cited by 30